NeuroOne (Nasdaq:NMTC) announced today that it filed an FDA 510(k) submission for its trigeminal nerve ablation technology.

Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial pain that does not respond ...

NeuroOne submits FDA filing early for trigeminal nerve ablation using its OneRF system as the facial pain market sees projected growth to $416 million by 2030.

Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial pain that does not respond well to conventional medical treatments, often leading to significant ...

The following is a summary of “Suicidal Ideation and Self-Injury in Trigeminal Neuralgia,” published in the April 2025 issue ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) filed its 510(k) submission to the FDA for trigeminal nerve ablation on Wednesday, earlier than previously guided. NeuroOne Medical is ...

That’s the brutal reality for sufferers of trigeminal neuralgia, a nerve disorder so painful it’s earned a chilling nickname: the “suicide disease.” Roughly 15,000 Americans are diagnosed ...

has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance.